Robust isolation of malignant plasma cells in multiple myeloma

Blood

Volumn 123, Issue 9, 2014, Pages 1336-1340

  Frigyesi, Ildikó ^a   Adolfsson, Jörgen ^a   Ali, Mina ^a   Christophersen, Mikael Kronborg ^a   Johnsson, Ellinor ^a   Turesson, Ingemar ^b   Gullberg, Urban ^a   Hansson, Markus ^a,b   Nilsson, Björn ^a,c,d  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c University and Regional Laboratories   (Sweden)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL MATURATION ANTIGEN; CD307E PROTEIN; CD319 PROTEIN; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; FKBP11 PROTEIN; G PROTEIN COUPLED RECEPTOR 5D; ITGA8 PROTEIN; PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; SDC1 PROTEIN, HUMAN; SLAMF7 PROTEIN, HUMAN; TNFRSF17 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CELL CLONING; CELL ISOLATION; CELL POPULATION; CELL STRUCTURE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; CULTURE TECHNIQUE; GENE DOSAGE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT PLASMA CELL; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BONE MARROW CELL; CELL SEPARATION; EVALUATION STUDY; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY;

B-CELL MATURATION ANTIGEN; BONE MARROW CELLS; CELL SEPARATION; HUMANS; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, IMMUNOLOGIC; REPRODUCIBILITY OF RESULTS; SYNDECAN-1; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899692195     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-529800     Document Type: Article

References (25)

1. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121(6):884-892.
2. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
3. Nilsson T, Höglund M, Lenhoff S, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age-and sex-related differences. Br J Haematol. 2003;120(6):960-969. (Pubitemid 36411554)
4. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482-488. (Pubitemid 38392955)
5. San Miguel JF, Gutiérrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42(11):1510-1519. (Pubitemid 44118776)
6. Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. J Immunol Methods. 1997;205(1):73-79. (Pubitemid 27297835)
7. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010;23(3):433-451.
8. Grigoriadis G, Whitehead S. CD138 shedding in plasma cell myeloma. Br J Haematol. 2010;150(3):249.
9. Boyd KD, Ross FM, Walker BA, et al; NCRI Haematology Oncology Studies Group. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17(24):7776-7784.
10. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-2553.
11. Kohlmann A, Kipps TJ, Rassenti LZ, et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008;142(5):802-807.
12. Verhaak RGW, Wouters BJ, Erpelinck CAJ, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
13. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica. 2011;96(2):221-230.
14. Metzeler KH, Hummel M, Bloomfield CD, et al; Cancer and Leukemia Group B; German AML Cooperative Group. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193-4201.
15. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951- 2959. (Pubitemid 37248870)
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):Article3.
17. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309.
18. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203-215.
19. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775-2784.
20. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552-559.
21. Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953-960.
22. Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol. 2013;41(4):387-397.e1.
23. Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232.
24. Ise T, Nagata S, Kreitman RJ, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007;21(1):169-174. (Pubitemid 44921849)
25. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14(3):277-289. (Pubitemid 32289292)